申请人:SMITHKLINE BEECHAM
LABORATOIRES PHARMACEUTIQUES
公开号:EP0303418A2
公开(公告)日:1989-02-15
A compound of formula (I), or a pharmaceutically acceptable salt thereof,
in which,
R₁ is hydrogen, lower alkyl or CH₂OR₆;
R₂ is hydrogen or lower alkyl;
R₃ is hydrogen or lower alkyl;
each of W and Z, which are different, represents -CR₄R₅- or -(CRxRy)n-, in which,
R₄ is hydrogen, C₁₋₃ alkyl, C₁₋₃ alkylthio or C₁₋₃ alkoxy;
R₅ is C₁₋₃ alkyl, C₁₋₃ alkylthio or C₁₋₃ alkoxy;
or together R₄ and R₅ form a 3 to 6 membered carbocyclic ring, or a heterocyclic ring containing one or two ring oxygen, nitrogen or sulphur atoms;
or R₄ and R₅ together form an oxo or methylene group;
each of Rx and Ry is hydrogen or C₁₋₃ alkyl; n is zero or 1;
R₆ is hydrogen, lower alkyl, lower alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, heteroarylcarbonyl, optionally substituted aminocarbonyl, lower alkoxycarbonyl and aryloxycarbonyl;
R₇ is hydrogen or lower alkyl;
X is oxygen or sulphur;
and A is sulphur, oxygen or -NH-,
is useful for the treatment of heart disease.
式 (I) 的化合物或其药学上可接受的盐、
其中
R₁ 是氢、低级烷基或 CH₂OR₆;
R₂ 是氢或低级烷基;
R₃ 是氢或低级烷基;
不同的W和Z各自代表-CR₄R₅-或-(CRxRy)n-,其中、
R₄ 是氢、C₁₋₃ 烷基、C₁₋₃ 烷硫基或 C₁₋₃ 烷氧基;
R₅ 是 C₁₋₃ 烷基、C₁₋₃烷硫基或 C₁₋₃ 烷氧基;
或 R₄ 和 R₅ 共同形成 3 至 6 个成员的碳环,或含有一个或两个环氧、氮或硫原子的杂环;
或 R₄ 和 R₅ 共同形成一个氧代或亚甲基;
Rx 和 Ry 各为氢或 C₁₋₃ 烷基;n 为 0 或 1;
R₆ 是氢、低级烷基、低级烷基羰基、芳基羰基、芳基羰基、杂芳基羰基、任选取代的氨基羰基、低级烷氧基羰基和芳氧基羰基;
R₇ 是氢或低级烷基;
X 是氧或硫;
A 是硫、氧或-NH-、
可用于治疗心脏病。